Not all biomarkers are the same. Learn about the differences between these two important classes.
From our Sept. 15 issue: Thanks to transfection innovations, protein characterization is available earlier in drug discovery.
Hope for better cancer treatments may lie in those patients in a trial who respond exceptionally well to a drug when most other participants do not.
From our Sept. 15 issue: Has "disease in a dish" come to seem not only flat, but also weary, stale, and unprofitable? Try "disease in a tissue"—a 3D in vitro assay approach.
Sandoz’s filgrastim could be a good test case as the company seeks FDA approval under the 351(k) abbreviated pathway.
A new industry leader reigns supreme this year.
Single-Use Sensors: TruFluor and TruTorr | Excellence in bio-processing measurement
Be sure to add firstname.lastname@example.org
to your Address Book or Safe Senders List.
here for instructions.
If you have any questions about your subscription, click
here to email us or call at (914) 740-2189.
You may also be interested in subscribing to the GEN magazine, an indispensable
resource for everyone involved in the business of translating discoveries at the
bench into solutions that fight disease and improve health, agriculture, and the
today to see why over 60,000 biotech professionals read GEN to
keep current in the areas of genomics, proteomics, drug discovery, biomarker discovery,
bioprocessing, molecular diagnostics, collaborations, biotech business trends, and
© 2014 Genetic Engineering & Biotechnology News All Rights Reserved